Date: May 27, 2021 Your Name: Zhe Zhang Manuscript Title: Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	testimony		
-		X N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11		V. Nove	
11	Stock or stock options	XNone	
12	12 Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
12			
	financial interests		

None

# Please place an "X" next to the following statement to indicate your agreement:

Date: May 27, 2021 Your Name: Sen Yang Manuscript Title: Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

S    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    _X_None      6    Payment for expert testimony    _X_None      7    Support for attending meetings and/or travel    _X_None      8    Patents planned, issued or pending    _X_None      9    Patents planned, issued or pending    _X_None      9    Patticipation on a Data Safety Monitoring Board or Advisory Board    _X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid    _X_None      11    Stock or stock options    _X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other    _X_None				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events	5	-	XNone	
manuscript writing or educational events		lectures, presentations,		
educational events		speakers bureaus,		
educational events		manuscript writing or		
testimony		educational events		
testimony	6	Payment for expert	X None	
7    Support for attending meetings and/or travel   XNone      7    Support for attending meetings and/or travel   XNone      8    Patents planned, issued or pending   XNone      9    Participation on a Data Safety Monitoring Board or Advisory Board   XNone      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   XNone      11    Stock or stock options   XNone      12    Receipt of equipment, materials, drugs, medical   XNone				
meetings and/or travel				
meetings and/or travel	7	Support for attending	X None	
8    Patents planned, issued or pending   XNone      9    Participation on a Data Safety Monitoring Board or Advisory Board   XNone      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   XNone      11    Stock or stock options   XNone      12    Receipt of equipment, materials, drugs, medical   XNone	'			
pending		meetings and or traver		
pending				
pending				
pending				
9    Participation on a Data Safety Monitoring Board or Advisory Board    _X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid    _X_None      11    Stock or stock options    _X_None      12    Receipt of equipment, materials, drugs, medical    _X_None	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board		pending		
Safety Monitoring Board or Advisory Board				
Safety Monitoring Board or Advisory Board	9	Participation on a Data	X None	
Advisory Board		-		
in other board, society, committee or advocacy group, paid or unpaid				
committee or advocacy group, paid or unpaid	10	Leadership or fiduciary role	XNone	
group, paid or unpaid		in other board, society,		
11  Stock or stock options XNone    12  Receipt of equipment, materials, drugs, medical XNone		committee or advocacy		
11  Stock or stock options XNone    12  Receipt of equipment, materials, drugs, medical XNone				
12  Receipt of equipment, materials, drugs, medical	11		V Nore	
materials, drugs, medical	11	Stock of stock options	XNone	
materials, drugs, medical				
materials, drugs, medical				
	12		XNone	
writing, gifts or other				
services		services		
13 Other financial or nonXNone	13	Other financial or non-	XNone	
financial interests		financial interests		

None

# Please place an "X" next to the following statement to indicate your agreement:

Date: May 27, 2021 Your Name: Yanfang Ma Manuscript Title: Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

S    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    _X_None      6    Payment for expert testimony    _X_None      7    Support for attending meetings and/or travel    _X_None      8    Patents planned, issued or pending    _X_None      9    Patents planned, issued or pending    _X_None      9    Patticipation on a Data Safety Monitoring Board or Advisory Board    _X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid    _X_None      11    Stock or stock options    _X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other    _X_None				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events	5	-	XNone	
manuscript writing or educational events		lectures, presentations,		
educational events		speakers bureaus,		
educational events		manuscript writing or		
testimony		educational events		
testimony	6	Payment for expert	X None	
7    Support for attending meetings and/or travel   XNone      7    Support for attending meetings and/or travel   XNone      8    Patents planned, issued or pending   XNone      9    Participation on a Data Safety Monitoring Board or Advisory Board   XNone      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   XNone      11    Stock or stock options   XNone      12    Receipt of equipment, materials, drugs, medical   XNone				
meetings and/or travel				
meetings and/or travel	7	Support for attending	X None	
8    Patents planned, issued or pending   XNone      9    Participation on a Data Safety Monitoring Board or Advisory Board   XNone      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   XNone      11    Stock or stock options   XNone      12    Receipt of equipment, materials, drugs, medical   XNone	'			
pending		meetings and or traver		
pending				
pending				
pending				
9    Participation on a Data Safety Monitoring Board or Advisory Board    _X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid    _X_None      11    Stock or stock options    _X_None      12    Receipt of equipment, materials, drugs, medical    _X_None	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board		pending		
Safety Monitoring Board or Advisory Board				
Safety Monitoring Board or Advisory Board	9	Participation on a Data	X None	
Advisory Board		-		
in other board, society, committee or advocacy group, paid or unpaid				
committee or advocacy group, paid or unpaid	10	Leadership or fiduciary role	XNone	
group, paid or unpaid		in other board, society,		
11  Stock or stock options XNone    12  Receipt of equipment, materials, drugs, medical XNone		committee or advocacy		
11  Stock or stock options XNone    12  Receipt of equipment, materials, drugs, medical XNone				
12  Receipt of equipment, materials, drugs, medical	11		V Nore	
materials, drugs, medical	11	Stock of stock options	XNone	
materials, drugs, medical				
materials, drugs, medical				
	12		XNone	
writing, gifts or other				
services		services		
13 Other financial or nonXNone	13	Other financial or non-	XNone	
financial interests		financial interests		

None

# Please place an "X" next to the following statement to indicate your agreement:

Date: May 27, 2021 Your Name: Hanqiong Zhou Manuscript Title: Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

S    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    _X_None      6    Payment for expert testimony    _X_None      7    Support for attending meetings and/or travel    _X_None      8    Patents planned, issued or pending    _X_None      9    Patents planned, issued or pending    _X_None      9    Patticipation on a Data Safety Monitoring Board or Advisory Board    _X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid    _X_None      11    Stock or stock options    _X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other    _X_None				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events	5	-	XNone	
manuscript writing or educational events		lectures, presentations,		
educational events		speakers bureaus,		
educational events		manuscript writing or		
testimony		educational events		
testimony	6	Payment for expert	X None	
7    Support for attending meetings and/or travel   XNone      7    Support for attending meetings and/or travel   XNone      8    Patents planned, issued or pending   XNone      9    Participation on a Data Safety Monitoring Board or Advisory Board   XNone      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   XNone      11    Stock or stock options   XNone      12    Receipt of equipment, materials, drugs, medical   XNone				
meetings and/or travel				
meetings and/or travel	7	Support for attending	X None	
8    Patents planned, issued or pending   XNone      9    Participation on a Data Safety Monitoring Board or Advisory Board   XNone      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   XNone      11    Stock or stock options   XNone      12    Receipt of equipment, materials, drugs, medical   XNone	'			
pending		meetings and or traver		
pending				
pending				
pending				
9    Participation on a Data Safety Monitoring Board or Advisory Board    _X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid    _X_None      11    Stock or stock options    _X_None      12    Receipt of equipment, materials, drugs, medical    _X_None	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board		pending		
Safety Monitoring Board or Advisory Board				
Safety Monitoring Board or Advisory Board	9	Participation on a Data	X None	
Advisory Board		-		
in other board, society, committee or advocacy group, paid or unpaid				
committee or advocacy group, paid or unpaid	10	Leadership or fiduciary role	XNone	
group, paid or unpaid		in other board, society,		
11  Stock or stock options XNone    12  Receipt of equipment, materials, drugs, medical XNone		committee or advocacy		
11  Stock or stock options XNone    12  Receipt of equipment, materials, drugs, medical XNone		-		
12  Receipt of equipment, materials, drugs, medical	11		V Nore	
materials, drugs, medical	11	Stock of stock options	XNone	
materials, drugs, medical				
materials, drugs, medical				
	12		XNone	
writing, gifts or other				
services		services		
13 Other financial or nonXNone	13	Other financial or non-	XNone	
financial interests		financial interests		

None

# Please place an "X" next to the following statement to indicate your agreement:

Date: May 27, 2021 Your Name: Xuan Wu Manuscript Title: Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

S    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    _X_None      6    Payment for expert testimony    _X_None      7    Support for attending meetings and/or travel    _X_None      8    Patents planned, issued or pending    _X_None      9    Patents planned, issued or pending    _X_None      9    Patticipation on a Data Safety Monitoring Board or Advisory Board    _X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid    _X_None      11    Stock or stock options    _X_None      12    Receipt of equipment, materials, drugs, medical writing, gifts or other    _X_None				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
lectures, presentations, speakers bureaus, manuscript writing or educational events				
speakers bureaus, manuscript writing or educational events	5	-	XNone	
manuscript writing or educational events		lectures, presentations,		
educational events		speakers bureaus,		
educational events		manuscript writing or		
testimony		educational events		
testimony	6	Payment for expert	X None	
7    Support for attending meetings and/or travel   XNone      7    Support for attending meetings and/or travel   XNone      8    Patents planned, issued or pending   XNone      9    Participation on a Data Safety Monitoring Board or Advisory Board   XNone      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   XNone      11    Stock or stock options   XNone      12    Receipt of equipment, materials, drugs, medical   XNone				
meetings and/or travel				
meetings and/or travel	7	Support for attending	X None	
8    Patents planned, issued or pending   XNone      9    Participation on a Data Safety Monitoring Board or Advisory Board   XNone      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid   XNone      11    Stock or stock options   XNone      12    Receipt of equipment, materials, drugs, medical   XNone	'			
pending		meetings and or traver		
pending				
pending				
pending				
9    Participation on a Data Safety Monitoring Board or Advisory Board    _X_None      10    Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid    _X_None      11    Stock or stock options    _X_None      12    Receipt of equipment, materials, drugs, medical    _X_None	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board		pending		
Safety Monitoring Board or Advisory Board				
Safety Monitoring Board or Advisory Board	9	Participation on a Data	X None	
Advisory Board		-		
in other board, society, committee or advocacy group, paid or unpaid				
committee or advocacy group, paid or unpaid	10	Leadership or fiduciary role	XNone	
group, paid or unpaid		in other board, society,		
11  Stock or stock options XNone    12  Receipt of equipment, materials, drugs, medical XNone		committee or advocacy		
11  Stock or stock options XNone    12  Receipt of equipment, materials, drugs, medical XNone				
12  Receipt of equipment, materials, drugs, medical	11		V Nore	
materials, drugs, medical	11	Stock of stock options	XNone	
materials, drugs, medical				
materials, drugs, medical				
	12		XNone	
writing, gifts or other				
services		services		
13 Other financial or nonXNone	13	Other financial or non-	XNone	
financial interests		financial interests		

None

# Please place an "X" next to the following statement to indicate your agreement:

Date: May 27, 2021 Your Name: Jing Han Manuscript Title: Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	testimony		
-		X N	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11		V. Nove	
11	Stock or stock options	XNone	
12	12 Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
12			
	financial interests		

None

# Please place an "X" next to the following statement to indicate your agreement:

Date: May 27, 2021 Your Name: Jiabao Hou Manuscript Title: Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None

# Please place an "X" next to the following statement to indicate your agreement:

Date: May 27, 2021 Your Name: Lidan Hao Manuscript Title: Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
Ŭ	pending		
	P 0.10118		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other	<u>├</u>	
	services		
13	Other financial or non-	XNone	
	financial interests		

None

# Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-05-18 Your Name: Jonathan D. Spicer Manuscript Title: Consistency of Recommendations for the Diagnosis and Treatment of Non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	AZ	
	any entity (if not indicated	Roche	
	in item #1 above).	Merck	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	AZ, BMS, Merck, Protalix, CLS Therapeutics X None	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	X_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	X_None	

Dr. Spicer received research grants from AZ, Roche and Merck and honoraria and consulting fees from AZ, BMS, Merck, Protalix and CLS Therapeutics; outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2021-05-03 Your Name: Young Wha Koh Manuscript Title: Consistency of Recommendations for the Diagnosis and Treatment of Non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone
	speakers bureaus, manuscript writing or educational events	
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	X_None
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

The author declares that there are no conflicts of interest.

Please place an "X" next to the following statement to indicate your agreement:

Date: 27 April 2021 Your Name: Mariano Provencio Manuscript Title: Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	BMS	
	any entity (if not indicated	Roche	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	BMS, Astra Zeneca, MSD, Angem, Roche, Takeda	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	X_None
	manuscript writing or educational events	
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	X_None
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone

Dr. Provencio received grants from BMS and Roche, and consulting fees BMS, Astra Zeneca, MSD, Angem, Roche and Takeda; all outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

Date: 28 April 2021 Your Name: Noemi Reguart Manuscript Title: Consistency of Recommendations for the Diagnosis and Treatment of Non-small cell lung cancer: a systematic review. Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	X_None	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

None

### Please place an "X" next to the following statement to indicate your agreement:

Date: 10 May, 2021 Your Name: Tesuya Mitsudomi Manuscript Title: Consistency of Recommendations for the Diagnosis and Treatment of Non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone			
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Boehringer ingelheim Asrtazeneca Ono Taiho Daiichi-Sankyo MSD X_None	Research grantResearch grantResearch grantResearch grantResearch grantResearch grant		
4	Consulting fees	_XNone			

5	Payment or honoraria for	AstraZeneca	
5	lectures, presentations,	Novartis	
	speakers bureaus,	Chugai	
	manuscript writing or	Amgen	
	educational events	MSD	
-		Eli-Lilly	
		Merck Biopharma	
-		Pfizer	
6	Devine ent feix evin ent	Boehringer Ingelheim	
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	AstraZeneca	
	Safety Monitoring Board or	Novartis	
	Advisory Board	Chugai	
		Amgen	
-		MSD	
-		Bristol Myers Squibb	
-		Boehringer Ingelheim	
10	Leadership or fiduciary role	IASLC	President
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		

Dr. Mitsudomi received research grants from Boehringer Ingelheim, Asrtazeneca, Ono, Taiho, Daiichi-Sankyo and MSD; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Novartis, Chugai, Amgen, MSD, Eli-Lilly, Merck Biopharma, Pfizer and Boehringer Ingelheim; participated on a data safety monitoring board or advisory board of AstraZeneca, Novartis, Chugai, Amgen, MSD, Bristol Myers Squibb, Boehringer Ingelheim; and served as president of IASLC.

#### Please place an "X" next to the following statement to indicate your agreement:

Date: May 27, 2021 Your Name: Qiming Wang Manuscript Title: Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review Manuscript number (if known): TLCR-21-423

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone				
		Time frame: past	36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone				
3	Royalties or licenses	XNone				
4	Consulting fees	XNone				

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
	<i>J</i>		
8	Patents planned, issued or pending	XNone	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	13 Other financial or non- financial interests	XNone	

None

# Please place an "X" next to the following statement to indicate your agreement: